ArticleAlcohol and alcoholism (Oxford, Oxfordshire)2026
Alcohol use disorder with metabolic dysfunction is associated with adverse sleep outcomes in a US clinical cohort.
Article in Alcohol and alcoholism (Oxford, Oxfordshire), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimSleep is critical to health, yet its relationship to metabolic dysfunction (MD) in alcohol use disorder (AUD) remains understudied in US clinical populations.
methods1359 participants were recruited through the Natural History Protocol at the National Institutes of Health and categorized into four groups: healthy controls (HC), individuals with MD only (metHC), individuals with current AUD without MD (AUD), and individuals with both current AUD and MD (metAUD). Sleep was assessed using the Pittsburgh Sleep Quality Index (PSQI). Multinomial logistic regression models were used to test associations between sleep metrics and group status, adjusting for age, race, and sex (Model 1), and additionally for education, income, and smoking status (Model 2). Additional models examined sleep outcomes by MD severity (mild, <3; severe, ≥3 criteria) among AUD.
resultsThousand two hundred twenty participants were included: 155 HC, 397 metHC, 77 AUD, and 591 metAUD. Adverse sleep outcomes were associated with increased odds of metHC, AUD, and metAUD groups compared to HC, with the strongest associations observed for metAUD across multiple PSQI domains. Each one-category increase in sleep disturbance was associated with an eleven-fold increase in odds of metAUD relative to HC (OR: 11.71, 95% CI, 6.90-19.86). Associations remained significant in Model 2. Sleep disturbance and daytime dysfunction were also associated with increased odds of severe MD compared to AUD-only (false discovery rate < 0.05).
conclusionsAdverse sleep outcomes were associated with increased odds of co-occurring MD in AUD, highlighting the clinical relevance of monitoring both sleep and metabolic health and the need for targeted intervention in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.